184 related articles for article (PubMed ID: 34598062)
1. Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for the treatment of solid tumors.
Xiao Y; Chen P; Luo C; Xu Z; Li X; Liu L; Zhao L
Cancer Treat Res Commun; 2021; 29():100467. PubMed ID: 34598062
[TBL] [Abstract][Full Text] [Related]
2. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.
Dai T; Sun H; Liban T; Vicente-Suarez I; Zhang B; Song Y; Jiang Z; Yu J; Sheng J; Lv B
Sci Rep; 2024 May; 14(1):10661. PubMed ID: 38724599
[TBL] [Abstract][Full Text] [Related]
3. ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation.
Yuwen H; Wang H; Li T; Ren Y; Zhang YK; Chen P; Sun A; Bian G; Li B; Flowers D; Presler M; Subramanian K; Xue J; Wang J; Lynch K; Mei J; He X; Shan B; Hou B
Cancer Res; 2024 May; 84(10):1680-1698. PubMed ID: 38501978
[TBL] [Abstract][Full Text] [Related]
4. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
[TBL] [Abstract][Full Text] [Related]
5. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
Hansen K; Kumar S; Logronio K; Whelan S; Qurashi S; Cheng HY; Drake A; Tang M; Wall P; Bernados D; Leung L; Ophir E; Alteber Z; Cojocaru G; Galperin M; Frenkel M; White M; Hunter J; Liang SC; Kotturi MF
Cancer Immunol Immunother; 2021 Dec; 70(12):3525-3540. PubMed ID: 33903974
[TBL] [Abstract][Full Text] [Related]
6. CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.
Mu Y; Guan X
Curr Med Chem; 2024; 31(13):1634-1645. PubMed ID: 38666504
[TBL] [Abstract][Full Text] [Related]
7. A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma.
Assal RA; Elemam NM; Mekky RY; Attia AA; Soliman AH; Gomaa AI; Efthimiadou EK; Braoudaki M; Fahmy SA; Youness RA
Transl Oncol; 2024 Jul; 45():101961. PubMed ID: 38631259
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors.
Yuan Y; Li J; Chen J; Han L; Wang L; Yue Y; Liu J; Zhang B; Yuan Y; Wu M; Bian Y; Xie Y; Zhu J
Biomed Pharmacother; 2024 May; 174():116565. PubMed ID: 38603888
[TBL] [Abstract][Full Text] [Related]
9. Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
Zhang P; Liu X; Gu Z; Jiang Z; Zhao S; Song Y; Yu J
Biomark Res; 2024 Jan; 12(1):7. PubMed ID: 38229100
[TBL] [Abstract][Full Text] [Related]
10. Striking the Balance with a PD-L1×4-1BB Bispecific Antibody.
Ha J; Grippin AJ; Kim BYS; Jiang W
Cancer Res; 2024 May; 84(10):1546-1547. PubMed ID: 38745496
[TBL] [Abstract][Full Text] [Related]
11. Hemin blocks TIGIT/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy.
Zhou X; Li Y; Zhang X; Li B; Jin S; Wu M; Zhou X; Dong Q; Du J; Zhai W; Wu Y; Qiu L; Li G; Qi Y; Zhao W; Gao Y
Sci China Life Sci; 2024 May; 67(5):996-1009. PubMed ID: 38324132
[TBL] [Abstract][Full Text] [Related]
12. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Cai L; Li Y; Tan J; Xu L; Li Y
J Hematol Oncol; 2023 Sep; 16(1):101. PubMed ID: 37670328
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy.
Geng Q; Jiao P
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257366
[TBL] [Abstract][Full Text] [Related]
14. Development of Plant-Derived Bispecific Monoclonal Antibody Targeting PD-L1 and CTLA-4 against Mouse Colorectal Cancer.
Bulaon CJI; Khorattanakulchai N; Rattanapisit K; Sun H; Pisuttinusart N; Phoolcharoen W
Planta Med; 2024 Apr; 90(4):305-315. PubMed ID: 38373705
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of TIGIT and PD-1 with a novel small molecule for cancer immunotherapy.
Li Y; Li B; Wang Q; Zhang X; Zhang Q; Zhou X; Shi R; Wu Y; Zhai W; Chen Z; Zhou X; Zhao W
Biochem Pharmacol; 2024 May; 223():116162. PubMed ID: 38527557
[TBL] [Abstract][Full Text] [Related]
16. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
Li T; Niu M; Zhou J; Wu K; Yi M
Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
[TBL] [Abstract][Full Text] [Related]
17. Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture.
Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2021; 12():669496. PubMed ID: 34040611
[TBL] [Abstract][Full Text] [Related]
18. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
Li E; Huang X; Zhang G; Liang T
J Exp Clin Cancer Res; 2021 Sep; 40(1):279. PubMed ID: 34479614
[TBL] [Abstract][Full Text] [Related]
19. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor.
Zhao J; Dong J; Deng C; Zhang Q; Sun S; Li H; Bai Y; Deng H
Oncoimmunology; 2023; 12(1):2265703. PubMed ID: 37808405
[TBL] [Abstract][Full Text] [Related]
20. TIGIT: a novel immunotherapy target moving from bench to bedside.
Solomon BL; Garrido-Laguna I
Cancer Immunol Immunother; 2018 Nov; 67(11):1659-1667. PubMed ID: 30232519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
